Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 Test is Used in the UK COVID-19 Human Challenge Study to Investigate the T C...
May 18 2021 - 9:15AM
Oxford Immunotec, a global, high-growth diagnostics company part of
PerkinElmer, today announced that its T-SPOT® Discovery SARS-CoV-2
kit is being used for T cell testing in the UK COVID-19 Human
Challenge Study, a national collaboration including the UK
government, the NHS, academia and the private sector. The study is
funded by the Department of Business, Energy, and Industrial
Strategy (BEIS) through the UK Vaccines Taskforce and is being
delivered through a partnership between government, hVIVO (part of
Open Orphan plc), Imperial College London, and The Royal Free
London NHS Foundation Trust.
The groundbreaking UK COVID-19 Human Challenge Study has global
importance as the first study of its type in the world, and the
data generated should help to develop vaccines against COVID-19
much more quickly and efficiently. The first stage of the trial,
which commenced in March, will enable identification of the most
appropriate dose of the virus needed to cause COVID-19 (SARS-CoV-2)
infection in a safe and controlled environment. The participants
will have a complete analysis of their immune response to infection
carried out (including T cells) which should lead to a better
understanding of the profile, magnitude, and duration of the immune
response to SARS-CoV-2. This study will therefore establish an
optimised dose and study design that will subsequently be used to
evaluate the efficacy of treatment and vaccine candidates,
including level and duration of immune protection, in follow-on
studies.
A custom version of Oxford Immunotec’s T-SPOT Discovery
SARS-CoV-2 kit (for research use only) will be used in this study.
The kit uses the T-SPOT technology platform, a standardized ELISPOT
methodology, to detect the T cell immune response in study
subjects. Understanding the T cell immune response, in addition to
the antibody response (via serology), may offer additional insights
into how the complete immune system responds to infection and
vaccination. As T cells are the first responders of the immune
system and are known to be long lived, using T cells to measure
immune response may overcome some of the limitations of serology
testing. A CE marked IVD version of the kit (the T-SPOT.COVID test)
is also available from Oxford Immunotec.
Dr. Magdalena Dudek, VP, Product Development at Oxford Immunotec
said, “The UK COVID-19 Human Challenge Study has global
significance, and the potential to be a much more efficient and
faster way to understand the disease and how our immune system
fights it. We are very excited to be a part of this trial which
should accelerate the development of vaccines and treatments
against COVID-19. We are proud of our continual partnership with
the UK Vaccines Taskforce which enables us to provide T cell
testing for this critical clinical trial.”
For further information about the study visit:
www.ukcovidchallenge.com For further information visit:
www.tspotdiscovery.com
T-SPOT Discovery SARS-CoV-2 is for
research use only, not for use in diagnostic
procedures.
About Oxford ImmunotecOxford Immunotec is
a global, high-growth diagnostics company and part of the
PerkinElmer group. We bring energy and invention to a world in need
of diagnostic truth. We are uniquely placed as the only company in
the world offering regulated ELISPOT assays for T cell measurement,
with approval around the globe. Our leading product, the T-SPOT.TB
test, is used for diagnosing infection with Tuberculosis, the
world’s largest cause of death from infectious disease. Oxford
Immunotec is an experienced manufacturer of IVD tests, operating
under a fully audited Quality Management System, ensuring rigorous
batch control. The company has manufactured in excess of 20 million
clinical T cell tests for TB infection. The T-SPOT.TB test has been
approved for sale in over 50 countries, including the United States
(where it has received pre-market approval from the Food and Drug
Administration), Europe (where it has obtained a CE mark), as well
as Japan and China. The recently released T-SPOT.COVID test is CE
marked in Europe for clinical use to detect the T cell immune
response to SARS-CoV-2 (www.tspotcovid.com). Oxford Immunotec is
headquartered near Oxford, U.K. and in Marlborough, MA. Additional
information can be found at www.oxfordimmunotec.com.
About PerkinElmerPerkinElmer enables
scientists, researchers and clinicians to address their most
critical challenges across science and healthcare. With a mission
focused on innovating for a healthier world, we deliver unique
solutions to serve the diagnostics, life sciences, food and applied
markets. We strategically partner with customers to enable earlier
and more accurate insights supported by deep market knowledge and
technical expertise. Our dedicated team of about 14,000 employees
worldwide is passionate about helping customers work to create
healthier families, improve the quality of life, and sustain the
wellbeing and longevity of people globally. The Company reported
revenue of approximately $3.8 billion in 2020, serves customers in
190 countries, and is a component of the S&P 500 index.
Additional information is available through 1-877-PKI-NYSE, or at
www.perkinelmer.com.
For Media Inquiries:
US: Mary ConwayMKC Strategies, LLCTel: +1 (516)
606-6545 MConway@MKCStrategies.com
UK: Megan AndersonZPB AssociatesMobile:
07597572287Office: (020) 7018
1124megan.anderson@zpb-associates.com
PerkinElmer (NYSE:PKI)
Historical Stock Chart
From Aug 2024 to Sep 2024
PerkinElmer (NYSE:PKI)
Historical Stock Chart
From Sep 2023 to Sep 2024